Novel Coronavirus Pneumonia
11
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
27%
3 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
NK Cells Treatment for COVID-19
Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
Effects of Fuzheng Huayu Tablets on COVID-19
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19
Efficacy and Safety of Corticosteroids in COVID-19
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
Protective Effect of Aspirin on COVID-19 Patients
The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia
Study for Novel Coronavirus Pneumonia (NCP)
A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection